Who we are

The From Testing to Targeted Treatment Program (FT3), established in 2020, is an independent, nonprofit global consortium of individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.

A patient-led global initiative:

8 Founding Members from patient community
Min. 40% patient representation on the Board
3 working groups co-led by patients

Project Team

Membership

Governance

Quotes from members